Medtronic Plc (MDT) Stock Price & Analysis
Medtronic Plc (MDT) rose 1.60% to USD 81.98 as of June 9, 2026 at 22:33 UTC, according to Nexqual real-time market data.
MDT last closed at USD 80.69; the session ranged USD 80.6–82.34 on volume of 7,557,051 shares. Market capitalization is $105.25B, with a 52-week range of USD 73.31–106.33 (NYQ). Source: Nexqual, June 9, 2026 at 22:33 UTC.
Key Statistics (as of June 9, 2026 at 22:33 UTC)
| Price | USD 81.98 |
|---|---|
| Change | ▲ 1.60% (up) |
| Previous Close | USD 80.69 |
| Open | USD 80.76 |
| Day Range | USD 80.6 – 82.34 |
| 52-Week Range | USD 73.31 – 106.33 |
| Volume | 7,557,051 shares |
| Market Cap | $105.25B |
| Exchange | NYQ |
Technical Analysis (MDT)
Nexqual's technical model rates MDT "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 22:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.48 (neutral) |
| vs SMA50 | Above (USD 81.07) |
| MACD | -0.08 (negative) |
Analyst Ratings (MDT)
Wall Street analysts rate MDT "Buy" based on 26 analysts, with a mean price target of USD 98.58 (range USD 78–121), per Nexqual as of June 9, 2026 at 22:33 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 98.58 |
| High Target | USD 121 |
| Low Target | USD 78 |
| Buy / Hold / Sell | 18 / 12 / 0 |
Earnings (MDT)
| Next Earnings Date | 2026-08-18 |
|---|---|
| EPS Estimate | USD 1.39 |
| Revenue Estimate | $9.55B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-04-30 | USD 1.55 vs est 1.54 ▲ beat |
| 2026-01-31 | USD 1.36 vs est 1.34 ▲ beat |
| 2025-10-31 | USD 1.36 vs est 1.31 ▲ beat |
| 2025-07-31 | USD 1.26 vs est 1.23 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financials & Fundamentals (MDT)
| Total Revenue | $36.36B |
|---|---|
| Revenue Growth (YoY) | +9.90% |
| Gross Margin | +65.38% |
| Operating Margin | +21.30% |
| Profit Margin | +13.20% |
| ROE | +9.93% |
| Debt / Equity | 57.06 |
| Total Cash | $8.38B |
| Total Debt | $28.07B |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financial Health Score (MDT)
Nexqual rates Medtronic Plc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:33 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 65%, operating 21% |
| Balance Sheet | Solid — $8.38B cash vs $28.1B debt |
| Cash Flow | Solid — Operating cash flow $7.33B |
| Efficiency | Mixed — ROE 10% |
Ownership (MDT)
| Insider Ownership | +0.31% |
|---|---|
| Institutional Ownership | +89.40% |
| Shares Outstanding | 1.28B |
| Float | 1.28B |
| Short % of Float | +1.14% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Leadership (MDT)
Medtronic Plc is led by Geoffrey Straub Martha (age 55), Chairman of the Board & CEO, per Nexqual as of June 9, 2026 at 22:33 UTC.
| Chairman of the Board & CEO | Geoffrey Straub Martha (age 55) |
|---|---|
| Executive VP & CFO | Thierry Pieton (age 55) |
| Senior VP and Chief Scientific & Medical Officer | Laura Mauri M.D., M.Sc. (age 55) |
| Vice President & Head of Investor Relations | Ingrid Goldberg |
| Senior Vice President of Human Resources, IT and Global Communications & Corporate Marketing | Matthew R. Walter (age 46) |
Major Backers & Investors (MDT)
Notable institutional backers of Medtronic Plc include Capital Group, JPMorgan, Bank of America Corporation, according to Nexqual as of June 9, 2026 at 22:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 4.04% |
| JPMorgan | 3.97% |
| Bank of America Corporation | 2.03% |
| Massachusetts Financial Services Co. | 1.67% |
| Morgan Stanley | 1.61% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.73% |
| BlackRock | 10.11% |
| State Street | 6% |
| Geode Capital | 2.24% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
From Medtronic Plc's Latest SEC 10-K Filing (filed 2025-06-20)
Key Strengths & Strategy (as disclosed to the SEC)
- FDA and other regulatory bodies, both in and outside the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the U.S.
- Intellectual Property and Litigation We rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements, including non-disclosure agreements, to protect our business and proprietary technology.
- Development by other companies of new or improved products, processes, technologies, or the 13 Table of Content introduction of reprocessed products or generic versions when our proprietary products lose their patent protection may make our existing or planned products less competitive.
- In order to continue to compete effectively, we must continue to create, invest in or acquire advanced technology, incorporate this technology into our proprietary products, obtain regulatory approvals in a timely manner, and successfully manufacture and market our products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABT | Abbott Laboratories | USD 91.25 | ▲ 0.2% |
| BSX | Boston Scientific Corporation | USD 48.96 | ▲ 0.84% |
| SYK | Stryker Corporation | USD 314.01 | ▲ 2.73% |
| AMGN | Amgen Inc. | USD 344.57 | ▼ 1.43% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:33 UTC. This page is informational and not investment advice.